Specialty Pharma Journal Specialty, Precision & Technology
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors. The study findings could help predict which patients will develop resistance to PARP inhibitors and allow doctors to alter treatment at the earliest possible opportunity. A team at The Institute …
Tag Archives: institute of cancer research
May, 2018
June, 2017
-
19 June
New Three-In-One Blood Test Opens Door to Precision Medicine for Prostate Cancer
Scientists have developed a three-in-one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes. By testing cancer DNA in the bloodstream, researchers found they could pick out which men with advanced prostate cancer were likely to …
-
5 June
ASCO 2017: Ovarian Cancer Drug Delivers ‘Very Promising’ Results in Early Trial
A new targeted treatment for ovarian cancer has shown ‘very promising’ results in an early clinical trial – shrinking tumors in half of women with the disease. Researchers believe the drug, which mimics the action of folic acid to enter cells, could hold huge promise for women with advanced ovarian …
October, 2015
-
16 October
New Test May Help Personalize Treatment for Childhood Cancer
A new gene test can identify which patients are likely to suffer more aggressive forms of the childhood cancer rhabdomyosarcoma, new research reports. Examining the activity of only five genes in a sample of the tumour was enough to identify high-risk children who might benefit from more intensive treatment or …
April, 2015
-
21 April
AstraZeneca’s Ovarian Cancer Drug Shows Promise in Treating Prostate Cancer
AstraZeneca’s recently approved ovarian cancer drug may also benefit men with prostate cancer, according to new clinical trial results. Results show that men with prostate cancer benefit from treatment with olaparib, the first cancer drug to target inherited mutations. AstraZeneca’s Lynparza (olaparib) was approved by the US Food and Drug …
January, 2015
-
22 January
Study Finds Gene Linked to Treatment-Resistance in Patients with Testicular Cancer
Scientists have uncovered several new genetic mutations that could drive testicular cancer, and have identified a gene that may play a role in tumors becoming resistant to available therapies. A new major research study, led by scientists at The Institute of Cancer Research, London, is the first to use state-of-the-art …